查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1971055

抗毒素市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、地區和競爭格局分類，2021-2031年

Anti-Venom Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Species (Snake, Scorpion, Spiders, and Other), By Type (Polyvalent Anti-venoms, Monovalent Anti-venom, and Other), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球抗毒素市場預計將從 2025 年的 13.8 億美元成長到 2031 年的 20.7 億美元，複合年成長率為 6.98%。

抗毒素是生物製藥，含有從免疫動物血漿中提取的抗體，旨在中和蛇咬傷和蜇傷產生的毒素。推動抗毒素市場成長的主要因素是全球蛇毒中毒病例的增加以及各國政府加強應對這種被忽視的熱帶疾病，這凸顯了開發能夠降低死亡率的可靠治療方法的迫切需求。根據世界衛生組織（世衛組織）2024年的數據，每年有180萬至270萬例蛇咬傷中毒病例，造成約81410至137880人死亡。

市場概覽
預測期 2027-2031
市場規模：2025年 13.8億美元
市場規模：2031年 20.7億美元
複合年成長率：2026-2031年 6.98%
成長最快的細分市場 免疫療法
最大的市場 北美洲

儘管有這些迫切需求，但由於高昂的製造成本以及在偏遠地區維持低溫運輸的物流複雜性，市場面臨巨大的障礙。這些因素推高了最終的治療成本，限制了低收入地區（這些地區的需求最為迫切）獲得治療的機會。因此，弱勢群體因無法獲得這些基本藥物而面臨的經濟困境仍然是阻礙全球市場進一步擴張的主要障礙。

市場促進因素

對新型和重組療法的研發投入不斷增加，正透過克服傳統血漿製品的局限性，改變全球抗毒素治療格局。製造商和研究機構日益關注小分子抑制劑和口服療法，這些療法即使在資源匱乏的環境中也能提供更優異的穩定性和便捷的給藥方式。大量資金支持著蛇咬傷治療的現代化，推動了這項創新。例如，2024年10月，阿姆斯特丹自由大學宣布，一個聯盟已獲得500萬歐元的資金，以推進口服蛇咬傷治療藥物的臨床試驗。此類投資將加速下一代療法的研發，並增強市場向偏遠地區供給能力。

政府主導的對抗被忽視的熱帶疾病的努力和資金投入發揮著至關重要的市場穩定作用，確保了穩定的需求和供應。公共部門透過與生產者建立正式的合作關係，並為高風險社區儲備抗毒素血清，從而降低與生產相關的商業風險。例如，2024年6月，澳洲政府擴大了其每年向巴布亞紐幾內亞捐贈至多600管瓶抗毒素血清的項目，加強了區域衛生安全。這項舉措凸顯了該領域的商業性潛力，而Mankind Pharma公司於2024年以約13,630印度盧比的價格收購Bharat Serums & Vaccines公司的協議，進一步表明了市場對成熟抗毒素血清技術的認可。

市場挑戰

全球抗毒素市場發展面臨的主要障礙是高昂的生產成本和嚴格的低溫運輸需求，這嚴重限制了低收入、高需求地區的取得途徑。抗毒素的生產需要耗費大量資源的生物程序，包括動物免疫，導致單位成本居高不下。此外，運輸過程中嚴格的溫度控制對於產品保鮮至關重要，這在蛇咬傷高發的偏遠地區造成了物流瓶頸。這些經濟和基礎設施方面的障礙造成了迫切的臨床需求與商業性現實之間的差距，受影響最嚴重的地區的人們往往無法負擔未經補貼的治療費用。

這個缺口限制了可實現的市場收入，因為如果沒有外部支持，潛在需求就無法轉化為永續的財務成長。資源匱乏加劇了這個問題，阻礙了穩定供應鏈和補貼成本的努力。例如，世界衛生組織（世衛組織）在2024年指出，其全球預防蛇咬傷策略所需營運預算將不到12%。這一巨大的資金缺口凸顯了嚴重的財務制約，阻礙了產品向最迫切需要的地區擴張，最終限制了整個產業的進步。

市場趨勢

人工智慧正在革新毒液表徵和藥物研發，減少了對傳統動物免疫的依賴，從而更有效地識別毒素中和分子。深度學習演算法能夠設計出特異性靶向致命毒液成分的合成蛋白，這些成分難以用傳統抗體捕獲。這項技術進步將提高治療藥物研發的速度和特異性，同時為血漿衍生產品提供可擴展的替代方案。例如，2025年1月，丹麥技術大學生物工程系報告稱，研究人員利用這些工具合成了一種蛋白質，該蛋白質使小鼠對致命的三指毒素的存活率達到了80-100%。

同時，為了應對緊急情況下識別特定蛇種的臨床挑戰，市場正轉向廣譜多價抗毒素製劑。在許多高發生地區，醫護人員缺乏診斷工具，因此，通用型抗毒素混合物對於降低不同蛇類致死風險至關重要。這一趨勢簡化了當地醫療中心的庫存管理，並確保了即時治療的可行性。作為這項進展的佐證，哥倫比亞大學2025年5月的一份報告重點介紹了能夠中和19種致命蛇毒的抗體混合物的研發，並在臨床前模型中證實了其對其中13種蛇毒的完全保護作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球抗毒素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 物種（蛇、蝎子、蜘蛛等）
    • 按類型（多價抗毒素、單價抗毒素、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美抗毒素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲抗毒素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區抗毒素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲抗毒素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美抗毒素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球抗毒素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Pfizer Inc.
  • Merck KGaA
  • Incepta Pharmaceuticals Limited
  • CSL Ltd.
  • Bharat Serums and Vaccines Ltd
  • Boston Scientific Corporation
  • Haffkine Bio-Pharmaceutical Corporation Limited
  • DEKA MELASRL
  • MicroPharm
  • Boehringer Ingelheim International GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23851

The Global Anti-Venom Market is projected to expand from USD 1.38 Billion in 2025 to USD 2.07 Billion by 2031, reflecting a CAGR of 6.98%. Anti-venom consists of biological preparations containing antibodies obtained from the plasma of immunized animals, designed to neutralize toxins from bites or stings. Growth is primarily driven by the increasing global prevalence of snake envenoming and strengthened government efforts to address this neglected tropical disease, creating a critical need for reliable therapeutics to reduce mortality rates. World Health Organization data from 2024 indicates that between 1.8 and 2.7 million snakebite poisoning cases occur annually, leading to approximately 81,410 to 137,880 deaths.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.38 Billion
Market Size 2031USD 2.07 Billion
CAGR 2026-20316.98%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

Despite this urgent need, the market faces significant hurdles due to high manufacturing costs and the logistical complexities of maintaining cold chains in isolated areas. These factors increase the final cost of treatment, limiting availability in low-income regions where the need is most acute. Consequently, the financial inability of vulnerable populations to access these essential medicines remains a major barrier that threatens to hinder the broader expansion of the global market.

Market Driver

Rising research and development investments in novel and recombinant therapeutics are transforming the global anti-venom landscape by overcoming the limitations of traditional plasma-based products. Manufacturers and research institutions are increasingly focusing on small molecule inhibitors and oral treatments that provide better stability and easier administration in resource-poor settings. This innovation is supported by significant funding to modernize snakebite care; for example, Vrije Universiteit Amsterdam announced in October 2024 that a consortium secured €5 million to advance clinical trials for oral snakebite drugs. These investments hasten the development of next-generation therapeutics, enhancing the market's ability to supply effective solutions to remote regions.

Government initiatives and funding for neglected tropical diseases act as vital market stabilizers by ensuring consistent demand and distribution. Public sector entities are formalizing partnerships with manufacturers to maintain antivenom stockpiles for at-risk populations, thereby reducing production-related commercial risks. Illustrating this, the Australian Government extended a program in June 2024 to donate up to 600 antivenom vials annually to Papua New Guinea, strengthening regional health security. This engagement highlights the sector's commercial potential, further evidenced by Mankind Pharma's 2024 agreement to acquire Bharat Serums and Vaccines for approximately INR 13,630 crore, emphasizing the value placed on established antivenom capabilities.

Market Challenge

A primary obstacle to the Global Anti-Venom Market's growth is the high cost of manufacturing combined with strict cold chain requirements, which severely restricts access in low-income, high-need regions. Producing antivenom requires a resource-intensive biological process involving animal immunization, resulting in high unit costs. Additionally, the rigorous temperature controls necessary to preserve these products during transport create logistical bottlenecks in remote areas where snakebites are most common. These economic and infrastructural barriers create a disconnect between urgent clinical needs and commercial realities, as populations with the highest incidence rates often lack the funds for unsubsidized treatments.

This gap limits addressable market revenue, as potential demand cannot be converted into sustainable financial growth without external support. Insufficient resources exacerbate the issue by stalling efforts to stabilize supply chains or subsidize costs. For instance, the World Health Organization noted in 2024 that the global strategy for snakebite prevention had secured less than 12% of its required operational budget. This significant funding shortfall highlights the severe financial constraints preventing the market from expanding into territories where its products are most critically needed, thereby capping overall industry progress.

Market Trends

Artificial intelligence is revolutionizing venom characterization and drug discovery by reducing reliance on traditional animal immunization to identify toxin-neutralizing molecules. Deep learning algorithms now enable the design of synthetic proteins that specifically target lethal venom components which often escape conventional antibodies. This technological advancement improves the speed and specificity of therapeutic development while offering a scalable alternative to plasma-derived products. For example, DTU Bioengineering reported in January 2025 that researchers utilized these tools to create proteins that achieved an 80 to 100% survival rate in mice against lethal three-finger toxins.

At the same time, the market is shifting toward broad-spectrum polyvalent antivenom formulations to address the clinical challenge of identifying specific snake species during emergencies. In many high-burden regions, healthcare providers lack diagnostic tools, making universal cocktails essential for mitigating mortality risks across diverse snake families. This trend simplifies inventory management for rural health centers and ensures immediate treatment viability. As evidence of this progress, a May 2025 report from Columbia University highlighted the development of an antibody cocktail capable of neutralizing neurotoxins from 19 deadly species, providing complete protection against 13 in preclinical models.

Key Market Players

  • Pfizer Inc.
  • Merck KGaA
  • Incepta Pharmaceuticals Limited
  • CSL Ltd.
  • Bharat Serums and Vaccines Ltd
  • Boston Scientific Corporation
  • Haffkine Bio-Pharmaceutical Corporation Limited
  • DEKA M.E.L.A. S.R.L
  • MicroPharm
  • Boehringer Ingelheim International GmbH

Report Scope

In this report, the Global Anti-Venom Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Venom Market, By Species

  • Snake
  • Scorpion
  • Spiders
  • Other

Anti-Venom Market, By Type

  • Polyvalent Anti-venoms
  • Monovalent Anti-venom
  • Other

Anti-Venom Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Venom Market.

Available Customizations:

Global Anti-Venom Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Venom Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Species (Snake, Scorpion, Spiders, Other)
    • 5.2.2. By Type (Polyvalent Anti-venoms, Monovalent Anti-venom, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Anti-Venom Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Species
    • 6.2.2. By Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anti-Venom Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Species
        • 6.3.1.2.2. By Type
    • 6.3.2. Canada Anti-Venom Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Species
        • 6.3.2.2.2. By Type
    • 6.3.3. Mexico Anti-Venom Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Species
        • 6.3.3.2.2. By Type

7. Europe Anti-Venom Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Species
    • 7.2.2. By Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anti-Venom Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Species
        • 7.3.1.2.2. By Type
    • 7.3.2. France Anti-Venom Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Species
        • 7.3.2.2.2. By Type
    • 7.3.3. United Kingdom Anti-Venom Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Species
        • 7.3.3.2.2. By Type
    • 7.3.4. Italy Anti-Venom Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Species
        • 7.3.4.2.2. By Type
    • 7.3.5. Spain Anti-Venom Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Species
        • 7.3.5.2.2. By Type

8. Asia Pacific Anti-Venom Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Species
    • 8.2.2. By Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anti-Venom Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Species
        • 8.3.1.2.2. By Type
    • 8.3.2. India Anti-Venom Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Species
        • 8.3.2.2.2. By Type
    • 8.3.3. Japan Anti-Venom Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Species
        • 8.3.3.2.2. By Type
    • 8.3.4. South Korea Anti-Venom Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Species
        • 8.3.4.2.2. By Type
    • 8.3.5. Australia Anti-Venom Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Species
        • 8.3.5.2.2. By Type

9. Middle East & Africa Anti-Venom Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Species
    • 9.2.2. By Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anti-Venom Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Species
        • 9.3.1.2.2. By Type
    • 9.3.2. UAE Anti-Venom Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Species
        • 9.3.2.2.2. By Type
    • 9.3.3. South Africa Anti-Venom Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Species
        • 9.3.3.2.2. By Type

10. South America Anti-Venom Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Species
    • 10.2.2. By Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anti-Venom Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Species
        • 10.3.1.2.2. By Type
    • 10.3.2. Colombia Anti-Venom Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Species
        • 10.3.2.2.2. By Type
    • 10.3.3. Argentina Anti-Venom Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Species
        • 10.3.3.2.2. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anti-Venom Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck KGaA
  • 15.3. Incepta Pharmaceuticals Limited
  • 15.4. CSL Ltd.
  • 15.5. Bharat Serums and Vaccines Ltd
  • 15.6. Boston Scientific Corporation
  • 15.7. Haffkine Bio-Pharmaceutical Corporation Limited
  • 15.8. DEKA M.E.L.A. S.R.L
  • 15.9. MicroPharm
  • 15.10. Boehringer Ingelheim International GmbH

16. Strategic Recommendations

17. About Us & Disclaimer